ClinicalTrials.gg
CompletedNCT04816669Updated Dec 23, 2022Results posted

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

A Phase 3 interventional study of BNT162b2 in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 21 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-23.

Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
629
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
23rd of 54
629 · median 575
Started
2021
with 29 others
Phase 3
18 of 54
1 open now
Registered
13th of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 23rd largest by enrollment, is one of 30 that started in 2021, is one of 18 in phase 3, and was the 13th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

This study will compare the safety and tolerability of lyophilized BNT162b2 presented in single dose vials to those of frozen-liquid BNT162b2 in multidose vials and determine whether the immune response is noninferior. Separately, the study will also describe the safety and immunogenicity of frozen-liquid BNT162b2 with lipid nanoparticle size at the upper end of specification and ready to use BNT162b2 (the immediate manufacturing precursor to the lyophilate). Additionally, the study will describe the safety and immunogenicity of an additional dose of frozen liquid BNT162b2 to participants who already received the 2-dose schedule of lyophilized BNT162b2.

  • 2-dose schedule (separated by 21 days)
  • At a dose of 30µg (as studied in the Phase 2/3 study C4591001)
  • In healthy adults 18 through 55 years of age
  • The duration of the study for each participant will be approximately 2 months (3 visits in total)
  • The study will be conducted in the United States
03

Conditions studied

  • SARS-CoV-2 Infection
  • COVID-19

Keywords

  • COVID-19
  • Coronavirus
  • Vaccine
  • SARS-CoV-2
  • RNA Vaccine
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants 18 - 55 years of age, inclusive, at Visit 1, (Day 1).
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Note: Healthy participants with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrolment, can be included.
  • Capable of giving personal signed , which includes compliance with the requirements and restrictions listed in the ICD and in the protocol.
  • For Dose 3: Participants who received BOTH doses of the lyophilized formulation of BNT162b2 as part of the initial study.

Exclusion criteria

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Known infection with , , or .
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
  • Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.
  • individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Previous vaccination with any coronavirus vaccine.
  • Receipt of medications intended to prevent COVID-19.
  • Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent), eg, for cancer or an disease, or planned receipt throughout the study. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  • Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.
  • Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation / Previous participation in other studies involving study intervention containing lipid nanoparticles (LNPs).
  • Previous participation in other studies involving study intervention containing lipid nanoparticles.
  • Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
629 participants (actual)

Study arms

  • Experimental
    Lyophilized SDV

    Biological: BNT162b2

  • Experimental
    Frozen liquid MDV (control for lyo SDV)

    Control for lyophilized SDV

    Biological: BNT162b2

  • Experimental
    Frozen-liquid with LNP size at the upper end of specification

    Biological: BNT162b2

  • Experimental
    RTU

    Biological: BNT162b2

  • Experimental
    Frozen liquid MDV (given as third dose following a primary series of lyophilized BNT162b2)

    Additional vaccine dose, using the frozen-liquid formulation, offered to participants who originally received 2 doses of the lyophilized formulation of BNT162b2

    Biological: BNT162b2

Interventions

  • BiologicalBNT162b2

    Intramuscular injection

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) of Full-Length S-Binding IgG Concentrations of Lyophilized Formulation SDVs and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2

    GMTs of full-length S-binding IgG level for lyophilized formulation in SDVs and frozen-Liquid formulation in MDVs were reported in this outcome measure as geometric mean concentration (GMCs) in descriptive data section. GMC and 95 percent (%) confidence interval (CI) were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Geometric mean ratio (GMR) was calculated as ratios of GMCs of BNT162b2 30 mcg lyophilized SDV and frozen-liquid MDV. GMR are reported in the statistical analysis section.

    Time frame: 1 Month after Dose 2

  2. Percentage of Participants With Local Reactions Within 7 Days After Dose 1

    Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination.

    Time frame: Within 7 days after Dose 1

  3. Percentage of Participants With Local Reactions Within 7 Days After Dose 2

    Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination.

    Time frame: Within 7 days after Dose 2

  4. Percentage of Participants With Systemic Events Within 7 Days After Dose 1

    Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C). Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 1 were reported.

    Time frame: Within 7 days after Dose 1

  5. Percentage of Participants With Systemic Events Within 7 Days After Dose 2

    Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 2 were reported.

    Time frame: Within 7 days after Dose 2

  6. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 2

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important medical event. AEs included all non-SAEs and SAEs. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Dose 1 up to 1 Month after Dose 2 (for approximately 2 months)

Secondary outcomes

  1. Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Part 1

    GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Baseline (Before Dose 1 on Day 1)

  2. Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 1

    GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: From Baseline (Before Dose 1 on Day 1) up to 1 Month after Dose 2

Other outcomes

  1. GMTs of Full-Length S-Binding IgG Concentrations of Frozen Liquid With LNP Size at Upper End of Specification and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2

    GMTs of full-length S-binding IgG level for frozen liquid with LNP size at upper end of specification relative to frozen-liquid formulation in MDVs were reported in this outcome measure as GMCs in descriptive data section. GMC and 95 % CI were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMR was calculated as ratios of GMCs of BNT162b2 30 mcg frozen liquid with LNP size at upper end of specification relative to frozen-liquid formulation in MDVs. GMR are reported in the statistical analysis section.

    Time frame: 1 Month after Dose 2

  2. GMCs of Full-length S-binding IgG Levels at Baseline and 1 Month After Dose 2: Part 2

    GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Baseline (Before Dose 1 on Day 1), 1 Month after Dose 2

  3. GMFRs in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 2

    GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: From Baseline (Before Dose 1 on Day 1) up to 1 Month after Dose 2

  4. Percentage of Participants With Local Reactions Within 7 Days After Dose 3

    Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 3.

    Time frame: Within 7 days after Dose 3

  5. Percentage of Participants With Systemic Events Within 7 Days After Dose 3

    Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C). Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 3 were reported.

    Time frame: Within 7 days after Dose 3

  6. Number of Participants With AEs and SAEs From Dose 3 to 1 Month After Dose 3

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important medical event. AEs included all non-SAEs and SAEs. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Dose 3 up to 1 Month after Dose 3 (1 month)

  7. GMFRs in Full-length S-binding IgG Levels From Before Dose 3 to 1 Month After Dose 3

    GMFRs were defined as ratios of the geometric mean concentration of IgG from 1 month after Dose 3 to geometric mean concentration of IgG before Dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: From before Dose 3 to 1 Month after Dose 3

  8. GMCs of Full-Length S-Binding IgG Levels at Baseline, 1 Month After Dose 2, Before Dose 3, and 1 Month After Dose 3

    GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Baseline, 1 Month after Dose 2, before Dose 3, and 1 Month after Dose 3

07

Results

Posted Dec 23, 2022

Participant flow

Part 1
Participant flow — Part 1
MilestoneBNT162b2 Lyophilized Single Dose Vial (SDV): Part 1BNT162b2 Frozen-Liquid Multi Dose Vial (MDV): Part 1BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2
Started27928000
Vaccinated at dose 127928000
Vaccinated at dose 227627700
Vaccination at dose 3114000
Completed27527400
Not completed4600
Withdrew: Adverse event1100
Withdrew: Lost to follow-up2200
Withdrew: Protocol violation0100
Withdrew: Withdrawal by subject1200
Part 2
Participant flow — Part 2
MilestoneBNT162b2 Lyophilized Single Dose Vial (SDV): Part 1BNT162b2 Frozen-Liquid Multi Dose Vial (MDV): Part 1BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2
Started003535
Vaccinated at dose 1003535
Vaccinated at dose 2003535
Completed003334
Not completed0021
Withdrew: Other0010
Withdrew: Withdrawal by subject0001
Withdrew: Lost to follow-up0010

Outcome measures

PrimaryGeometric Mean Titers (GMTs) of Full-Length S-Binding IgG Concentrations of Lyophilized Formulation SDVs and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2

GMTs of full-length S-binding IgG level for lyophilized formulation in SDVs and frozen-Liquid formulation in MDVs were reported in this outcome measure as geometric mean concentration (GMCs) in descriptive data section. GMC and 95 percent (%) confidence interval (CI) were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Geometric mean ratio (GMR) was calculated as ratios of GMCs of BNT162b2 30 mcg lyophilized SDV and frozen-liquid MDV. GMR are reported in the statistical analysis section.

Time frame:
1 Month after Dose 2
Reported as:
Geometric mean · Unit per milliliter
Geometric Mean Titers (GMTs) of Full-Length S-Binding IgG Concentrations of Lyophilized Formulation SDVs and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2
Unit per milliliterBNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1
Geometric Mean Titers (GMTs) of Full-Length S-Binding IgG Concentrations of Lyophilized Formulation SDVs and Frozen-Liquid Formulation in MDVs 1 Month After Dose 24796.8 (4414.1 to 5212.8)7031.6 (6393.6 to 7733.3)
Statistical analysis
  • BNT162b2 Lyophilized SDV: Part 1 vs BNT162b2 Frozen-Liquid MDV: Part 1 · Geometric mean ratio: 0.68 · 95% CI 0.60 to 0.77GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the concentrations BNT162b2 lyophilized SDV - BNT162b2 frozen-liquid MDV and the corresponding CI (based on the Student t distribution).
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 1

Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination.

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 1
Percentage of participantsBNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2
Redness4.0 (2.0 to 7.0)5.0 (2.8 to 8.2)0 (0.0 to 10.0)2.9 (0.1 to 14.9)
Swelling3.6 (1.7 to 6.5)3.6 (1.7 to 6.5)0 (0.0 to 10.0)5.7 (0.7 to 19.2)
Pain at Injection Site78.1 (72.7 to 82.8)87.1 (82.6 to 90.8)85.7 (69.7 to 95.2)68.6 (50.7 to 83.1)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 2

Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination.

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 2
Percentage of participantsBNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2
Redness3.6 (1.8 to 6.6)5.5 (3.1 to 8.9)0 (0.0 to 10.0)0 (0.0 to 10.0)
Swelling2.9 (1.3 to 5.7)3.3 (1.5 to 6.1)0 (0.0 to 10.0)8.6 (1.8 to 23.1)
Pain at Injection Site71.2 (65.4 to 76.5)80.3 (75.1 to 84.8)71.4 (53.7 to 85.4)62.9 (44.9 to 78.5)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 1

Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C). Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 1 were reported.

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 1
Percentage of participantsBNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2
Fever >=38.0 degree C0 (0.0 to 1.3)3.2 (1.5 to 6.0)0 (0.0 to 10.0)0 (0.0 to 10.0)
Fatigue46.4 (40.4 to 52.5)57.5 (51.5 to 63.4)54.3 (36.6 to 71.2)45.7 (28.8 to 63.4)
Headache31.3 (25.9 to 37.1)44.3 (38.4 to 50.3)37.1 (21.5 to 55.1)31.4 (16.9 to 49.3)
Chills8.6 (5.6 to 12.6)18.6 (14.2 to 23.6)8.6 (1.8 to 23.1)8.6 (1.8 to 23.1)
Vomiting2.9 (1.3 to 5.6)2.1 (0.8 to 4.6)5.7 (0.7 to 19.2)2.9 (0.1 to 14.9)
Diarrhea14.4 (10.5 to 19.1)13.9 (10.1 to 18.5)5.7 (0.7 to 19.2)11.4 (3.2 to 26.7)
New or worsened muscle pain16.5 (12.4 to 21.4)27.1 (22.0 to 32.8)11.4 (3.2 to 26.7)20.0 (8.4 to 36.9)
New or worsened joint pain7.9 (5.0 to 11.7)15.4 (11.3 to 20.1)11.4 (3.2 to 26.7)17.1 (6.6 to 33.6)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 2

Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 2 were reported.

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 2
Percentage of participantsBNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2
Fever >=38.0 degree C6.2 (3.7 to 9.7)12.4 (8.7 to 16.9)2.9 (0.1 to 14.9)5.7 (0.7 to 19.2)
Fatigue60.9 (54.9 to 66.8)75.2 (69.6 to 80.2)48.6 (31.4 to 66.0)60.0 (42.1 to 76.1)
Headache48.2 (42.1 to 54.3)61.7 (55.6 to 67.5)40.0 (23.9 to 57.9)40.0 (23.9 to 57.9)
Chills27.7 (22.5 to 33.4)46.4 (40.3 to 52.4)22.9 (10.4 to 40.1)17.1 (6.6 to 33.6)
Vomiting3.6 (1.8 to 6.6)2.2 (0.8 to 4.7)2.9 (0.1 to 14.9)0 (0.0 to 10.0)
Diarrhea12.8 (9.1 to 17.3)14.6 (10.6 to 19.3)8.6 (1.8 to 23.1)14.3 (4.8 to 30.3)
New or worsened muscle pain32.8 (27.3 to 38.8)43.1 (37.1 to 49.2)20.0 (8.4 to 36.9)37.1 (21.5 to 55.1)
New or worsened joint pain16.8 (12.6 to 21.8)32.1 (26.6 to 38.0)11.4 (3.2 to 26.7)28.6 (14.6 to 46.3)
PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 2

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important medical event. AEs included all non-SAEs and SAEs. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Dose 1 up to 1 Month after Dose 2 (for approximately 2 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 2
ParticipantsBNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2
AEs162144
SAEs0000
SecondaryGeometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Part 1

GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Baseline (Before Dose 1 on Day 1)
Reported as:
Geometric mean · Unit per milliliter
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Part 1
Unit per milliliterBNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Part 12.2 (1.8 to 2.6)2.2 (1.8 to 2.6)
SecondaryGeometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 1

GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
From Baseline (Before Dose 1 on Day 1) up to 1 Month after Dose 2
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 1
Fold riseBNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 12189.0 (1841.6 to 2601.9)3194.0 (2665.8 to 3826.8)
Other pre-specifiedGMTs of Full-Length S-Binding IgG Concentrations of Frozen Liquid With LNP Size at Upper End of Specification and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2

GMTs of full-length S-binding IgG level for frozen liquid with LNP size at upper end of specification relative to frozen-liquid formulation in MDVs were reported in this outcome measure as GMCs in descriptive data section. GMC and 95 % CI were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMR was calculated as ratios of GMCs of BNT162b2 30 mcg frozen liquid with LNP size at upper end of specification relative to frozen-liquid formulation in MDVs. GMR are reported in the statistical analysis section.

Time frame:
1 Month after Dose 2
Reported as:
Geometric mean · Unit per milliliter
GMTs of Full-Length S-Binding IgG Concentrations of Frozen Liquid With LNP Size at Upper End of Specification and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2
Unit per milliliterBNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2
GMTs of Full-Length S-Binding IgG Concentrations of Frozen Liquid With LNP Size at Upper End of Specification and Frozen-Liquid Formulation in MDVs 1 Month After Dose 27773.3 (5758.5 to 10493.1)6839.9 (5242.9 to 8923.5)
Statistical analysis
  • BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 vs BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 · Geometric mean ratio: 1.14 · 95% CI 0.77 to 1.68GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the concentrations BNT162b2 frozen-liquid LNP - BNT162b2 frozen-liquid RTU and the corresponding CI (based on the Student t distribution).
Other pre-specifiedGMCs of Full-length S-binding IgG Levels at Baseline and 1 Month After Dose 2: Part 2

GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Baseline (Before Dose 1 on Day 1), 1 Month after Dose 2
Reported as:
Geometric mean · Unit per milliliter
GMCs of Full-length S-binding IgG Levels at Baseline and 1 Month After Dose 2: Part 2
Unit per milliliterBNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2
Baseline2.3 (1.3 to 4.3)3.3 (1.6 to 6.7)
1 Month after Dose 27773.3 (5758.5 to 10493.1)6839.9 (5242.9 to 8923.5)
Other pre-specifiedGMFRs in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 2

GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
From Baseline (Before Dose 1 on Day 1) up to 1 Month after Dose 2
Reported as:
Geometric mean · Fold rise
GMFRs in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 2
Fold riseBNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2
GMFRs in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 23339.1 (1662.6 to 6706.4)2072.1 (987.5 to 4348.0)
Other pre-specifiedPercentage of Participants With Local Reactions Within 7 Days After Dose 3

Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 3.

Time frame:
Within 7 days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 3
Percentage of participantsBNT162b2 Frozen-Liquid MDV: Dose 3
Redness6.5 (2.7 to 13.0)
Swelling6.5 (2.7 to 13.0)
Pain at Injection Site70.1 (60.5 to 78.6)
Other pre-specifiedPercentage of Participants With Systemic Events Within 7 Days After Dose 3

Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C). Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 3 were reported.

Time frame:
Within 7 days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 3
Percentage of participantsBNT162b2 Frozen-Liquid MDV: Dose 3
Fever >=38.0 degree C8.4 (3.9 to 15.4)
Fatigue63.6 (53.7 to 72.6)
Headache52.3 (42.5 to 62.1)
Chills39.3 (30.0 to 49.2)
Vomiting2.8 (0.6 to 8.0)
Diarrhea13.1 (7.3 to 21.0)
New or worsened muscle pain29.0 (20.6 to 38.5)
New or worsened joint pain16.8 (10.3 to 25.3)
Use of antipyretic or pain medication35.5 (26.5 to 45.4)
Other pre-specifiedNumber of Participants With AEs and SAEs From Dose 3 to 1 Month After Dose 3

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important medical event. AEs included all non-SAEs and SAEs. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Dose 3 up to 1 Month after Dose 3 (1 month)
Reported as:
Count of participants · Participants
Number of Participants With AEs and SAEs From Dose 3 to 1 Month After Dose 3
ParticipantsBNT162b2 Frozen-Liquid MDV: Dose 3
AEs10
SAEs0
Other pre-specifiedGMFRs in Full-length S-binding IgG Levels From Before Dose 3 to 1 Month After Dose 3

GMFRs were defined as ratios of the geometric mean concentration of IgG from 1 month after Dose 3 to geometric mean concentration of IgG before Dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
From before Dose 3 to 1 Month after Dose 3
Reported as:
Geometric mean · Fold rise
GMFRs in Full-length S-binding IgG Levels From Before Dose 3 to 1 Month After Dose 3
Fold riseBNT162b2 Frozen-Liquid MDV: Dose 3
GMFRs in Full-length S-binding IgG Levels From Before Dose 3 to 1 Month After Dose 316.0 (13.9 to 18.5)
Other pre-specifiedGMCs of Full-Length S-Binding IgG Levels at Baseline, 1 Month After Dose 2, Before Dose 3, and 1 Month After Dose 3

GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Baseline, 1 Month after Dose 2, before Dose 3, and 1 Month after Dose 3
Reported as:
Geometric mean · Unit per milliliter
GMCs of Full-Length S-Binding IgG Levels at Baseline, 1 Month After Dose 2, Before Dose 3, and 1 Month After Dose 3
Unit per milliliterBNT162b2 Frozen-Liquid MDV: Dose 3
Baseline2.1 (1.6 to 2.7)
1 Month after Dose 24612.2 (4065.7 to 5232.1)
Before Dose 3874.4 (735.6 to 1039.4)
1 Month after Dose 314006.7 (11902.7 to 16482.7)

Adverse events

Collected over AEs and SAEs- For Part 1 and Part 2: Day 1 of Dose 1 up to 1 Month after Dose 2 (approximately2 months); Dose 3: From Dose 3 to 1 Month after Dose 3 (up to 1 month); Local reactions/systemic events (systematic collection): Within 7 days after each dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BNT162b2 Lyophilized SDV: Part 10/279 (0%)0/279 (0%)262/279 (93.9%)
BNT162b2 Frozen-Liquid MDV: Part 10/280 (0%)0/280 (0%)274/280 (97.9%)
BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 20/35 (0%)0/35 (0%)33/35 (94.3%)
BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 20/35 (0%)0/35 (0%)31/35 (88.6%)
BNT162b2 Frozen-Liquid MDV: Dose 30/114 (0%)0/114 (0%)87/114 (76.3%)
Most frequent other events
Showing 10 of 67
Most frequent other events
EventBNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2BNT162b2 Frozen-Liquid MDV: Dose 3
Injection site pain (PAIN)General disorders240/279261/28031/3528/3575/114
Fatigue (FATIGUE)General disorders199/279233/28024/3524/3568/114
Headache (HEADACHE)Nervous system disorders162/279198/28018/3519/3556/114
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders116/279153/2809/3516/3531/114
Chills (CHILLS)General disorders84/279148/2809/359/3542/114
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders61/279103/2808/3513/3518/114
Diarrhoea (DIARRHEA)Gastrointestinal disorders64/27971/2805/357/3514/114
Pyrexia (FEVER)General disorders17/27941/2801/352/359/114
Injection site swelling (SWELLING)General disorders17/27918/2800/354/357/114
Vomiting (VOMITING)Gastrointestinal disorders16/27912/2803/351/353/114

Baseline characteristics

Safety population set included all randomized participants who received at least 1 dose of the study intervention.

Age, Categorical
Age, Categorical(Participants)BNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1BNT162b2 Frozen-Liquid With LNP Size: Part 2BNT162b2 Frozen-Liquid With RTU Size: Part 2Total
<=18 years00000
Between 18 and 65 years2792803535629
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)BNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1BNT162b2 Frozen-Liquid With LNP Size: Part 2BNT162b2 Frozen-Liquid With RTU Size: Part 2Total
Female1431262018307
Male1361541517322
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1BNT162b2 Frozen-Liquid With LNP Size: Part 2BNT162b2 Frozen-Liquid With RTU Size: Part 2Total
Hispanic or Latino575559126
Not Hispanic or Latino2192213025495
Unknown or Not Reported34018
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BNT162b2 Lyophilized SDV: Part 1BNT162b2 Frozen-Liquid MDV: Part 1BNT162b2 Frozen-Liquid With LNP Size: Part 2BNT162b2 Frozen-Liquid With RTU Size: Part 2Total
American Indian or Alaska Native02002
Asian26166351
Native Hawaiian or Other Pacific Islander32005
Black or African American19342358
White2282202428500
More than one race352010
Unknown or Not Reported01113
08

Study locations

21 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Research Centers of America ( Hollywood )
    Hollywood, Florida 33024, United States
  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
    Jacksonville, Florida 32256, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 32801, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Kentucky Pediatric/ Adult Research
    Bardstown, Kentucky 40004, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • Amici Clinical Research LLC
    Raritan, New Jersey 08869, United States
  • Accellacare (formerly PMG Research of Wilmington, LLC)
    Wilmington, North Carolina 28401, United States
  • Aventiv Research Inc
    Columbus, Ohio 43213, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • University of Texas Medical Branch
    Galveston, Texas 77555, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • DM Clinical Research (Administrative and Storage Office only)
    Tomball, Texas 77375, United States
  • Martin Diagnostic Clinic
    Tomball, Texas 77375, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Dec 2021, 8 months.

Results were first posted in Dec 2022, 1 year after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 8 months is close to that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2021
First posted
Mar 25, 2021
StartActual
Apr 1, 2021
Primary completionActual
Dec 1, 2021
CompletionActual
Dec 2, 2021
Results first posted
Dec 23, 2022
Last update
Dec 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04816669
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 25, 2021
Start date
Apr 1, 2021
Primary completion
Dec 1, 2021
Completion
Dec 2, 2021
Results posted
Dec 23, 2022
Last update
Dec 23, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion